Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer

The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma

(2018) Bianca Simon et al.   EXPERIMENTAL DERMATOLOGY

Driving cars to the clinic for solid tumors

(2018) Mauro Castellarin et al.   GENE THERAPY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

(2018) Bianca Simon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Emerging Cellular Therapies for Cancer

(2018) Sonia Guedan et al.   Annual Review of Immunology

CAR-T cell therapy in melanoma: A future success story?

(2018) Bianca Simon et al.   EXPERIMENTAL DERMATOLOGY

Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies

(2018) Dora Hammerl et al.   TRENDS IN IMMUNOLOGY

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

(2017) Yong-Chen Lu et al.   JOURNAL OF CLINICAL ONCOLOGY

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy

(2017) Felipe Bedoya et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

(2016) Clare Y. Slaney et al.   CLINICAL CANCER RESEARCH

Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma

(2016) Ugur Uslu et al.   EXPERIMENTAL DERMATOLOGY

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

Generation of CD8+T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy

(2015) Sandra Höfflin et al.   CANCER BIOLOGY & THERAPY

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

(2015) Christian Krug et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Engineered T cells for cancer therapy

(2014) Carl H. June et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells

(2014) Alessandro Poggi et al.   IMMUNOLOGY LETTERS

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

PMEL: a pigment cell-specific model for functional amyloid formation

(2013) Brenda Watt et al.   Pigment Cell & Melanoma Research

Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence

(2012) Brian M Olson et al.   Expert Review of Vaccines

Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes

(2011) C. Hofmann et al.   BLOOD

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD